All In Biotech

Drug Trial Radar · NCT06319313

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC

Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 534 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

534

Planned (sponsor's estimate)

Start

May 1, 2024

Primary completion

Jul 1, 2026

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer (sqNSCLC).

Conditions

  • Squamous Cell Non-small Cell Lung Cancer

Interventions

  • JMT101Drug

    JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.

  • docetaxelDrug

    50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.

  • HB1801Drug

    75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: Up to approximately 2 years
  2. Overall Survival (OS)Time frame: Up to approximately 3 years
  3. Incidence and severity of adverse events (AE) and serious adverse events (SAE)Time frame: Up to approximately 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.